Genomic Health (GHDX) Given “Buy” Rating at Canaccord Genuity

Canaccord Genuity restated their buy rating on shares of Genomic Health (NASDAQ:GHDX) in a research report report published on Tuesday morning. They currently have a $42.00 target price on the medical research company’s stock.

Several other equities analysts also recently commented on GHDX. Zacks Investment Research downgraded shares of Genomic Health from a hold rating to a sell rating in a report on Wednesday, October 4th. Jefferies Group reiterated a hold rating and set a $34.00 price target on shares of Genomic Health in a report on Friday, October 20th. ValuEngine downgraded shares of Genomic Health from a hold rating to a sell rating in a report on Thursday, November 9th. JPMorgan Chase & Co. downgraded shares of Genomic Health from a neutral rating to an underweight rating and set a $25.00 price target on the stock. in a report on Wednesday, December 13th. Finally, BidaskClub upgraded shares of Genomic Health from a sell rating to a hold rating in a report on Tuesday, December 19th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the company. The company has an average rating of Hold and a consensus price target of $32.14.

Shares of Genomic Health (NASDAQ GHDX) traded down $0.79 during trading hours on Tuesday, reaching $34.61. 116,100 shares of the company traded hands, compared to its average volume of 170,360. The company has a market cap of $1,231.40, a P/E ratio of -288.42 and a beta of 0.66. Genomic Health has a one year low of $26.37 and a one year high of $37.50.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Wednesday, November 8th. The medical research company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.04. Genomic Health had a negative net margin of 1.30% and a negative return on equity of 1.79%. analysts forecast that Genomic Health will post -0.08 EPS for the current year.

In other Genomic Health news, insider Laura Leber sold 21,000 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $33.29, for a total value of $699,090.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider James J. Vaughn sold 1,379 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total transaction of $44,831.29. The disclosure for this sale can be found here. Over the last three months, insiders sold 65,717 shares of company stock valued at $2,158,232. 46.20% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in GHDX. Schwab Charles Investment Management Inc. boosted its position in Genomic Health by 3.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 497,340 shares of the medical research company’s stock valued at $16,189,000 after buying an additional 14,665 shares during the period. First Trust Advisors LP boosted its position in Genomic Health by 53.9% in the 2nd quarter. First Trust Advisors LP now owns 33,949 shares of the medical research company’s stock valued at $1,105,000 after buying an additional 11,885 shares during the period. Rhumbline Advisers boosted its position in Genomic Health by 5.5% in the 2nd quarter. Rhumbline Advisers now owns 24,664 shares of the medical research company’s stock valued at $803,000 after buying an additional 1,296 shares during the period. SG Americas Securities LLC boosted its position in Genomic Health by 37.8% in the 2nd quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock valued at $199,000 after buying an additional 1,679 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in Genomic Health by 1.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 89,714 shares of the medical research company’s stock valued at $2,921,000 after buying an additional 1,137 shares during the period. 89.83% of the stock is owned by institutional investors.

WARNING: This article was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/01/17/genomic-health-ghdx-given-buy-rating-at-canaccord-genuity.html.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply